




STATE MEDICAID P&T COMMITTEE MEETING

Thursday, July 17, 2014

7:00 a.m. to 8:30 a.m.

Cannon Health Building

Room 128



MINUTES

Committee Members Present:

Lisa Hunt, R.Ph.

Elizabeth Young, Pharm.D.

Roger Martenau, M.D.

Jameson Rice, Pharm.D.

Ellie Brownstein, M.D.

Julia Ozbolt, M.D.

Committee Members Excused:

Beth Johnson, R.Ph.

Kort Delost, R.Ph.

Dept. of Health/Div. of Health Care Financing Staff Present:

Richard Sorenson, RN

Trevor Smith, CPhT

Tim Morley, R.Ph.

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Other Individuals Present:

Cody Ball, Select Health

Travis Bastow, UofU

Alicia Watkins, UofU

Gary Oderda, UofU

Meeting conducted by: Lisa Hunt

1. **Review and Approval of May Minutes:** Minutes for May were reviewed. Ellie Brownstein made a motion to approve the May minutes, Julia Ozbolt seconded the motion. All in favor.
2. **Housekeeping:** Lisa Hunt reminded people in attendance today to sign in. Lisa also reported that new classes were added to the Preferred Drug List on July first.
3. **Drug Utilization Review (DUR) Board update:** Lisa Hunt reported that the DUR board reviewed Hepatitis C drugs and established PA criteria for Olysio and Sovaldi during the July meeting.
4. **Vitamin D analogues:** Melissa Archer presented a review of the vitamin D analogue agent drug class. She presented peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines and Utah Medicaid utilization data was presented.
5. **No Public Comment**

6. **Committee discussion**

- a. Lisa Hunt presented the other states report including PDLs in the drug class for other states.
- b. Discussion by the committee that they want to separate the formulations and make separate motions for oral, injectable, and topical products.
- c. Ellie Brownstein made a motion to include at least one of each formulation in the PDL. Roger Martenau seconded the motion, all in favor.
- d. Julia Ozbolt made a motion that the oral agents are equally safe and efficacious. Ellie Brownstein seconded the motion. All in favor.
- e. Jamison Rice made a motion that the injectable products are equally safe and effective for inclusion on the PDL.
- f. Elizabeth Young made a motion that the topical products are equally safe and efficacious. Ellie Brownstein seconded the motion, all in favor.

7. **Bile Acid Sequestrants:** Melissa Archer presented a review of the bile acid sequestrant agent drug class. She presented peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines and Utah Medicaid utilization data was presented.

8. **No Public Comment**

9. **Committee discussion**

- a. Lisa Hunt presented the other states report including PDLs in the drug class for other states.
- b. Tim Morley asked for more details about usage of the drug with people who have genetic related hypercholesterolemia. He asked if one of these drugs would be better for patients with this diagnosis. Melissa said that this drug is not recommended for people who have the genetic disorder of hypercholesterolemia.
- c. Ellie Brownstein made a motion that the agents are equally safe and efficacious for inclusion in the PDL. Roger Martenau seconded the motion. All voted in favor.

10. **Meeting Adjourned**

11. Next meeting is scheduled for August 21, 2014. Hepatitis C agents will be discussed.

Minutes prepared by Trevor Smith

Recording available upon request, send email to medicaidpharmacy@utah.gov